Gra

phic

s D

OM

INIQ

UE

HA

MO

T -

Pho

togr

aphy

UR

IEL

CH

AN

TRA

INE

, ALE

XAN

DR

E L

ESC

UR

E/I

NST

ITU

T C

UR

IE

A center of excellence for thoracic

diseases

About institut CurieA leading player in the fight against cancer, Institut Curie boasts an internationally-renowned research center with a state-of-the-art hospital group that treats all types of cancer, including the rarest forms.

Founded in 1909 by Marie Curie, Institut Curie has three sites (Paris, Saint-Cloud and Orsay) with over 3,400 researchers, physicians and caregivers wor-king in support of its three missions: research, treatment, and the preservation and dissemination of knowledge.

Our project for the future, the 2015-2020 institu-tional project (MC21), is directly inspired by the model created by Marie Curie in 1909 to gather researchers and physicians together so as to bring new treatments to patients as quickly as possible.

Find out more at curie.fr

About institut MutuAliste Montsouris – iMMCreated in 1999 after the merger of the University of Paris’ International Hospital and the Porte de Choisy surgical center, the IMM is a private health institution of collective interest accessible to all without additional non-reimbursed fees.

It is multi-disciplinary, offering care through a medical and surgical team from a number of fields. The IMM is a center for excellence in research and teaching, is at the forefront of technological innovations, and is one of France’s top institutions.

Find out more at imm.fr

An innoVAtiVe PArtnersHiPDue to their complementary nature and their geo-graphical proximity, Institut Curie and Institut Mutualiste Montsouris have pooled their medical and scientific skills and their respiratory medicine resources by creating the Institut du thorax Curie-Montsouris.

tHe AiMs oF tHe institut du tHorAx Curie-Montsouris• To improve the care and treatment of patients with chest diseases.• To pool all skills so as to achieve overall care for cancer of the lung, pleura and mediastinum.• To ensure access to innovation at all stages of the disease.

+33 (0)1 84 95 95 00 contact@thoraxparis.fr

thorax-curie-montsouris.com

InSTITUT MUTUAlISTe MOnTSOUrIS 42 Blvd. Jourdan 75014 Paris

InSTITUT CUrIe 26 rue d’Ulm 75005 Paris

CurieSite

Curie-MontSouriS SiteS

CHeST TUMOr InVeSTIGATIOn CenTer (CITT)

InTerVenTIOnAl rADIOlOGY

reSeArCH

ADDITIOnAl eXAMS1. IMAGInG2. AnATOMY AnD PATHOlOGICAl CYTOlOGY3. BIOlOGICAl reSOUrCe CenTer - GeneTIC AnAlYSeS

MontSouriSSite

reSPIrATOrY MeDICIne

SPeCIAlIZeD enDOSCOPY

SUrGerY

MeDICAl OnCOlOGY

rADIOTHerAPY

OnCOGerIATrICS

SUPPOrTIVe CAre

« Clinical research lies at the heart of the

project, offering access to early trials for as many

patients as possible. The Institut du thorax

Curie-Montsouris thus has access to translational research, vital for therapeutic

innovation, which requires a shared biological resource center. »

Prof niColaS GirarDHeAD OF THe InSTITUT DU THOrAX CUrIe-MOnTSOUrIS

reseArCH And teACHinGThe strategy of the Institut du thorax Curie-Montsouris lies in research’s ability to innovate and to offer new treatments, both medical and surgical. Clinical trials, including early ones, concerning the immune response in particular, lie at the heart of the project.

The Institut du thorax Curie-Montsouris thus relies on a cutting-edge technical platform, the most complete one in the Paris region. Its role is to offer patients therapeutic innovations and to take part in research into chest diseases.

A PersonAliZed Course oF CAreTreatments for chest diseases are becoming in-creasingly personalized and require the expertise of multi-disciplinary teams.

The collective expertise at Institut Curie and the Institut Mutualiste Montsouris provides overall care for patients, discussed in a multidisciplinary consultation meeting (rCP) involving an expert practitioner in each specialty at the Institut du thorax Curie-Montsouris.

The aim of the Institut du thorax Curie-Montsouris is to create an individualized course of care for the patient, for which each step (screening, diagnosis, treatment and follow-up) will be managed by a multi-disciplinary team that is flexible, humane, quick and efficient, from the very first appointment onward.

Patients also have access to the medical environ-ment of both organizations and a cutting-edge technical platform for medical imaging, biopatho-logy and radiotherapy.

ACCelerAtinG ACCeSS to tHe lAtest INNOVATIONS And to eARLY TRIALS

1,400 PATIenTS TreATeD eACH YeAr AT THe InSTITUT DU THOrAX CUrIe-MOnTSOUrIS

40,000 neW lUnG CAnCer CASeS eACH YeAr In FrAnCe

30% SUrVIVAl AT 3 YeArS, In THe lOnG TerM, THAnKS TO IMMUnOTHerAPY